Respiratory Syncytial Virus Therapeutics Market

Respiratory Syncytial Virus Therapeutics Market (Drug Type: Palivizumab, Ribavirin, and Others; and Dosage Form: Oral, Injectable, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Respiratory Syncytial Virus Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 1.1 Bn in 2022
  • It is expected to advance at a CAGR of 14.6% from 2023 to 2031 and reach US$ 3.8 Bn by the end of 2031

Analyst Viewpoint

Extensive research in treatment of Respiratory Syncytial Virus (RSV) infections and growth in incidence of RSV infections are primary factors augmenting the global Respiratory Syncytial Virus therapeutics market revenue.

RSV causes respiratory disorders, with infants and the aging population at higher risk of contraction. Research regarding therapeutics (vaccines and drugs) began in 1960s; however, just one to two medications stand approved as of now.

Presence of several drugs under clinical trials and approvals is also fostering Respiratory Syncytial Virus therapeutics industry development.

Respiratory Syncytial Virus therapeutics market manufacturers are striving to introduce combined medications – orally administered as well as injectable drugs – for RSV infections. Significant unmet need for innovative RSV therapeutics for infants has created lucrative Respiratory Syncytial Virus Therapeutics business opportunities for companies operating in the sector.

Market Introduction

Respiratory Syncytial Virus (RSV) is a type of respiratory virus that primarily affects infants and young children, and also the geriatric population. Those with weaker immune systems are also at higher risk of contracting RSV infection.

RSV therapeutics and drugs operate by inhibiting the replication of the virus, thereby reducing duration of the illness and its severity. Research is underway regarding development of monoclonal antibodies (mAbs). These are being designed for binding to specific viral cells or proteins for blocking the viral entry or promoting clearance of virus by the immune system.

Various vaccine candidates including subunit, live attenuated, and nanoparticle-based vaccines are under clinical development. With the exception of a vaccine approved in 2023, the other modes of treatment as well as vaccines are at the nascent stage of development.

The time taken from conceptualization to approval of therapeutics for RSV is quite long. This is a key factor that is hampering the Respiratory Syncytial Virus therapeutics market size to a certain extent.

Extensive Research in Treatment of RSV Infections Fostering Respiratory Syncytial Virus Therapeutics Market Growth

RSV is a complex virus that presents challenges with regards to understanding pathogenesis, immune response, and the probable therapeutic targets. Several pharmaceutical firms are experiencing challenges regarding development of medications for RSV infection.

SYNAGIS (palivizumab) is the only medication approved in the last 20 years, with the recent breakthrough being Arexvy (vaccine) from GlaxoSmithKline. There is immense scope for emerging antiviral drugs for RSV infection in the RSV antiviral medications market, as their approval would provide patients access to a sizable number of medications.

Several drugs are in pipeline for trials and approvals from regulatory bodies such as the US FDA. Thus, the Respiratory Syncytial Virus therapeutics market forecast appears promising owing to the efforts of companies to introduce drugs and therapies for RSV infections.

Growth in Incidence of Respiratory Syncytial Virus (RSV) Infections Driving Market Progress

Human respiratory syncytial virus is one of the common causes of lower respiratory tract infections in people of all age groups. In those aged six and below, the first infection may result in bronchiolitis, which could prove fatal at times.

In those aged between six and 60 (especially the ones without comorbidities), repeated upper respiratory tract infections are observed, which range between subclinical infection and symptomatic upper respiratory tract disease.

For individuals aged 60 and above, the risk of severe RSV infection increases with the occurrence of underlying chronic pulmonary disease, functional disability, and circulatory conditions. Those who have undergone lung or bone marrow transplantation are also more prone to the RSV disease.

As per the International Journal of Infectious Diseases, mortality is the highest in children aged five and below and the elderly aged above 65. UNICEF states that approximately 650 million of the global population comprises children aged five and below, while the World Bank states that 10% of the same global population comprises those aged 65 and above.

Thus, rise in incidence of RSV infections across the globe is a prominent factor that is propelling market statistics.

Respiratory Syncytial Virus Therapeutics Market Regional Insights

North America accounted for the largest Respiratory Syncytial Virus therapeutics market share in 2022. The region is projected to maintain its dominance across the globe during the forecast period.

High share of North America can be ascribed to the rise in incidence of RSV infections in the region. As per the Center for Disease Control and Prevention, RSV infection alone results in 2.4 million outpatient visits among those aged below five in the U.S. Thus, the RSV treatment market is likely to grow substantially in the region in the near future.

Asia Pacific is expected to record significant market expansion during the forecast period. Presence of sophisticated healthcare infrastructure in Australia and Japan is driving the Respiratory Syncytial Virus therapeutics industry in the region.

On the other hand, countries such as India and China are striving to increase awareness regarding RSV infection and treatments among millennials. In 2023, the Beijing Center for Disease Prevention and Control unveiled the Beijing Major Respiratory Epidemic Disease Center with the objective of advancing its understanding of transmission of disease, diagnostic methods, proper control strategies, and various early warning symptoms.

Analysis of Key Players

Companies operating in the global Respiratory Syncytial Virus therapeutics market are conducting clinical trials regarding RSV therapeutics. For instance, in March 2022, AstraZeneca, during MEDLEY Phase 2/3 study, reported plausible tolerance and safety findings for a long-acting antibody medication called nirsevimab (a long-acting antibody medication that is especially deigned to treat babies at a higher risk of RSV infection).

The Respiratory Syncytial Virus therapeutics market report highlights prominent companies such as F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc., Medivir AB, and Teva Pharmaceuticals Industries Ltd. based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In May 2023, GlaxoSmithKline plc announced that the US FDA had approved its respiratory syncytial virus vaccine (adjuvanted) called Arexvy to do away with lower respiratory tract disease (LRTD) contracted from RSV infection in those aged 60 and above
  • In November 2022, Pfizer Inc. announced that the US FDA had accepted its respiratory vaccine candidate PF-06928316/RSVpreF. This RSV therapeutic helps prevent lower respiratory tract infection (MA-LRTI) and extreme MA-LRTI caused due to RSV infection in infants aged up to six months.
  • In October 2020, Moderna, Inc. confirmed that it had reclaimed rights to respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck & Co.

Respiratory Syncytial Virus Therapeutics Market Snapshot

Attribute Detail
Market Size in 2022 US$ 1.1 Bn
Market Forecast (Value) in 2031 US$ 3.8 Bn
Market Growth Rate (CAGR) 14.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Type
    • Palivizumab
    • Ribavirin
    • Others
  • Dosage Form
    • Oral
    • Injectable
    • Others
  • Distribution Channel
    • Drug Stores and Retail Pharmacies
    • Hospital Pharmacies
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • South Africa
  • Brazil
  • Mexico
  • GCC
Companies Profiled
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • AbbVie, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • GlaxoSmithKline plc
  • ReViral Ltd.
  • Gilead Sciences, Inc.
  • Medivir AB
  • Teva Pharmaceuticals Industries Ltd.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global respiratory syncytial virus therapeutics market in 2022?

It was valued at US$ 1.1 Bn in 2022

How is respiratory syncytial virus therapeutics business expected to grow during the forecast period?

It is projected to advance at a CAGR of 14.6% from 2023 to 2031

What are the key factors driving the demand for respiratory syncytial virus therapeutics?

Extensive research in treatment of RSV infections and growth in incidence of RSV infections

Which respiratory syncytial virus therapeutics distribution channel segment held the largest share in 2022?

The drug stores and retail pharmacies segment accounted for the largest share in 2022

Which region dominated the global respiratory syncytial virus therapeutics landscape in 2022?

North America was the dominant region in 2022

Who are the key respiratory syncytial virus therapeutic drug manufacturers?

F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck 7 Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc., Medivir AB, and Teva Pharmaceuticals Industries Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Respiratory Syncytial Virus (RSV) Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Drug Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Type, 2017–2031

            6.3.1. Palivizumab

            6.3.2. Ribavirin

            6.3.3. Others

        6.4. Market Attractiveness Analysis, by Drug Type

    7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Dosage Form

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Dosage Form, 2017–2031

            7.3.1. Oral

            7.3.2. Injectable

            7.3.3. Others

        7.4. Market Attractiveness Analysis, by Dosage Form

    8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Drug Stores and Retail Pharmacies

            8.3.2. Hospital Pharmacies

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Dosage Form

    9. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Drug Type, 2017–2031

            10.3.1. Palivizumab

            10.3.2. Ribavirin

            10.3.3. Others

        10.4. Market Value Forecast, by Dosage Form, 2017–2031

            10.4.1. Oral

            10.4.2. Injectable

            10.4.3. Others

        10.5. Market Value Forecast, by Distribution Channel, 2017–2031

            10.5.1. Drug Stores and Retail Pharmacies

            10.5.2. Hospital Pharmacies

            10.5.3. Others

        10.6. Market Value Forecast, by Country, 2017–2031

            10.6.1. U.S.

            10.6.2. Canada

        10.7. Market Attractiveness Analysis

            10.7.1. By Drug Type

            10.7.2. By Dosage Form

            10.7.3. By Distribution Channel

            10.7.4. By Country

    11. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Drug Type, 2017–2031

            11.3.1. Palivizumab

            11.3.2. Ribavirin

            11.3.3. Others

        11.4. Market Value Forecast, by Dosage Form, 2017–2031

            11.4.1. Oral

            11.4.2. Injectable

            11.4.3. Others

        11.5. Market Value Forecast, by Distribution Channel, 2017–2031

            11.5.1. Drug Stores and Retail Pharmacies

            11.5.2. Hospital Pharmacies

            11.5.3. Others

        11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Drug Type

            11.7.2. By Dosage Form

            11.7.3. By Distribution Channel

            11.7.4. By Country/Sub-region

    12. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Drug Type, 2017–2031

            12.3.1. Palivizumab

            12.3.2. Ribavirin

            12.3.3. Others

        12.4. Market Value Forecast, by Dosage Form, 2017–2031

            12.4.1. Oral

            12.4.2. Injectable

            12.4.3. Others

        12.5. Market Value Forecast, by Distribution Channel, 2017–2031

            12.5.1. Drug Stores and Retail Pharmacies

            12.5.2. Hospital Pharmacies

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Drug Type

            12.7.2. By Dosage Form

            12.7.3. By Distribution Channel

            12.7.4. By Country/Sub-region

    13. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Drug Type, 2017–2031

            13.3.1. Palivizumab

            13.3.2. Ribavirin

            13.3.3. Others

        13.4. Market Value Forecast, by Dosage Form, 2017–2031

            13.4.1. Oral

            13.4.2. Injectable

            13.4.3. Others

        13.5. Market Value Forecast, by Distribution Channel, 2017–2031

            13.5.1. Drug Stores and Retail Pharmacies

            13.5.2. Hospital Pharmacies

            13.5.3. Others

        13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.6.1. Brazil

            13.6.2. Mexico

            13.6.3. Rest of Latin America

        13.7. Market Attractiveness Analysis

            13.7.1. By Drug Type

            13.7.2. By Dosage Form

            13.7.3. By Distribution Channel

            13.7.4. By Country/Sub-region

    14. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Drug Type, 2017–2031

            14.3.1. Palivizumab

            14.3.2. Ribavirin

            14.3.3. Others

        14.4. Market Value Forecast, by Dosage Form, 2017–2031

            14.4.1. Oral

            14.4.2. Injectable

            14.4.3. Others

        14.5. Market Value Forecast, by Distribution Channel, 2017–2031

            14.5.1. Drug Stores and Retail Pharmacies

            14.5.2. Hospital Pharmacies

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Drug Type

            14.7.2. By Dosage Form

            14.7.3. By Distribution Channel

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. F. Hoffmann-La Roche Ltd.

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. AstraZeneca plc

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. Merck & Co., Inc.

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. AbbVie, Inc.

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. Valeant Pharmaceuticals International, Inc.

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. GlaxoSmithKline plc

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. ReViral Ltd.

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Gilead Sciences, Inc.

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

            15.3.9. Medivir AB

                15.3.9.1. Company Overview

                15.3.9.2. Product Portfolio

                15.3.9.3. SWOT Analysis

                15.3.9.4. Financial Overview

                15.3.9.5. Strategic Overview

            15.3.10. Teva Pharmaceuticals Industries Ltd.

                15.3.10.1. Company Overview

                15.3.10.2. Product Portfolio

                15.3.10.3. SWOT Analysis

                15.3.10.4. Financial Overview

                15.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 23: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017–2031

    Table 24: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

    Figure 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Drug Type, 2022

    Figure 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2022

    Figure 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Dosage Form, 2022

    Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Dosage Form, 2022

    Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022

    Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2022

    Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Region, 2022

    Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast, 2023–2031

    Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Region, 2022–2031

    Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2023–2031

    Figure 18: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

    Figure 20: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country, 2022–2031

    Figure 21: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 27: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 30: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 36: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 39: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 45: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 47: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 48: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

    Figure 54: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 56: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 57: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022–2031

    Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022–2031

    Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

    Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023–2031

    Figure 61: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023–2031

    Figure 62: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved